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1522Objective: In previous studies cholesterol-rich nanoemulsions (LDE) resembling low-density lipoprotein were
shown to concentrate in atherosclerotic lesions of rabbits. Lesions were pronouncedly reduced by treatment with
paclitaxel associated with LDE. This study aimed to test the hypothesis of whether LDE–paclitaxel is able to
concentrate in grafted hearts of rabbits and to ameliorate coronary allograft vasculopathy after the transplanta-
tion procedure.
Methods: Twenty-one New Zealand rabbits fed 0.5% cholesterol were submitted to heterotopic heart transplan-
tation at the cervical position. All rabbits undergoing transplantation were treated with cyclosporin A (10 mg $
kg1 $ d1 bymouth). Eleven rabbits were treated with LDE–paclitaxel (4 mg/kg body weight paclitaxel per week
administered intravenously for 6 weeks), and 10 control rabbits were treated with 3 mL/wk intravenous saline.
Four control animals were injected with LDE labeled with [14C]-cholesteryl oleate ether to determine tissue
uptake.
Results: Radioactive LDE uptake by grafts was 4-fold that of native hearts. In both groups the coronary arteries
of native hearts showed no stenosis, but treatment with LDE–paclitaxel reduced the degree of stenosis in grafted
hearts by 50%. The arterial luminal area in grafts of the treated group was 3-fold larger than in control animals.
LDE–paclitaxel treatment resulted in a 7-fold reduction of macrophage infiltration. In grafted hearts LDE–
paclitaxel treatment reduced the width of the intimal layer and inhibited the destruction of the medial layer.
No toxicity was observed in rabbits receiving LDE–paclitaxel treatment.
Conclusions: LDE–paclitaxel improved posttransplantation injury to the grafted heart. The novel therapeutic
approach for heart transplantation management validated here is thus a promising strategy to be explored in
future clinical studies. (J Thorac Cardiovasc Surg 2011;141:1522-8)Heart transplantation is the gold standard treatment for pa-
tients with severe cardiac failure for whom the standard
clinical or surgical alternatives would not be consistently
beneficial.1 The introduction of cyclosporin A in the
1980s was the breakthrough that made room for the world-
wide increase in the number of procedures and heart trans-
plantation facilities.2 Nonetheless, despite developments in
the management of patients after transplantation, the
success of heart grafts is still limited by the acute rejection
process and, in the long run, by coronary allograft vasculop-
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The Journal of Thoracic and Cardiovascular Surfecting the coronary arteries of the grafted heart, which can
lead to arrhythmia, myocardial infarction, congestive heart
failure, or sudden death. By the fifth year after transplanta-
tion, the incidence of disease can be as high as half of
patients undergoing transplantation.3
Coronary allograft vasculopathy is an inflammatory–
proliferative process that is uniquely diffuse and concentric.
Differently from coronary artery disease, coronary allograft
vasculopathy plaques are more cellular, are less calcified,
and have higher quantities of cholesterol and fat.4 Coronary
graft disease predominantly affects the distal vessels,
although it can also exhibit proximal lesions.3 This distal ves-
sel feature poses an additional problem because percutaneous
coronary interventions and coronary artery bypass are inef-
fective as treatmentmodalities. In this settingmanagement af-
ter heart transplantation awaits new therapeutic approaches to
circumvent or efficiently deal with those critical drawbacks.
Recently, we showed that cholesterol-rich nanoemul-
sions (LDE) that resemble the lipid structure of low-
density lipoprotein (LDL) and bind to LDL receptors5
have the ability to concentrate in lesional arteries of rabbits
with atherosclerosis induced by a cholesterol-rich diet.6
When the atherosclerotic rabbits were treated with the anti-
proliferative agent paclitaxel associated with LDE, there
was a 60% reduction of the lesion area in the aorta. Thegery c June 2011
Abbreviations and Acronyms
LDE ¼ cholesterol-rich nanoemulsion
LDL ¼ low-density lipoprotein
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treatment. There was no observable toxicity.6
Paclitaxel is one of the most effective antiproliferative
anticancer drugs,7 acting through inhibition of the disas-
sembly of microtubules and promotion of microtubule poly-
merization. Thus paclitaxel inhibits mitosis by interfering
with the formation of the mitotic spindle. The microtubules
formed in the presence of paclitaxel are markedly stable and
dysfunctional. This causes cell death by disrupting the nor-
mal microtubule dynamics required for cell division and vi-
tal interphase processes.7 A strong objection to paclitaxel
use in the cardiovascular therapeutic arsenal is its toxicity,
which is a serious drawback for the systemic treatment.8
However, in preclinical experiments we have shown that
when carried by LDE, paclitaxel toxicity was pronouncedly
reduced, as indicated by a 9-fold increase in the median le-
thal dose in mice.9 Tested in a pilot clinical assay in patients
with breast cancer, LDE–paclitaxel had virtually no observ-
able toxicity at the dose range routinely used in paclitaxel
chemotherapy (175–220 mg/m2 body surface every 3
weeks).10 Paclitaxel incorporation into LDE and the stabil-
ity of the LDE–drug association in the bloodstream is im-
proved by addition of an oleyl group to paclitaxel’s
chemical structure to increase the lipophilicity.9 The result-
ing complex LDE–paclitaxel oleate (LDE–paclitaxel) was
fairly stable, as shown in vitro in mice9 and in studies in
patients with cancer.11
The consistent antiproliferative–anti-inflammatory ac-
tion of LDE–paclitaxel with the marked reduction of the
atherosclerotic process in rabbits, as well as the pronounced
toxicity reduction documented at the clinical trial level,
prompted us to test the hypothesis of whether LDE–pacli-
taxel has the ability to ameliorate the immunologically in-
duced inflammatory–proliferative process that supervenes
in the grafted heart after transplantation in rabbits submitted
to heart transplantation.
MATERIALS AND METHODS
Animals and Experimental Protocols
Twenty-onemale NewZealandWhite rabbits weighing 3.4 0.6 kg and
21 male New Zealand Red rabbits weighing 2.7  0.5 kg (means  stan-
dard errors of the mean) were housed in individual cages in a tempera-
ture-controlled room (20C–22C) on a 12-hour light/dark cycle during
the experimental period. The white rabbits were the heart graft recipients,
and the red rabbits were the heart graft donors. The recipient rabbits were
allocated to one of 2 experimental groups. The LDE–paclitaxel group con-
sisted of 11 rabbits undergoing heterotopic heart transplantation at the cer-
vical position and treated with 4 mg/kg body weight paclitaxel associated
with LDE intravenously once a week beginning on the day of the procedureThe Journal of Thoracic and Carand during the ensuing 6 weeks. The control group consisted of 10 control
rabbits undergoing heterotopic heart transplantation at the cervical position
and with 3 mL of saline solution administered intravenously during the
ensuing 6 weeks.
During this period, all animals were fed regular chow with added 0.5%
cholesterol. Immunosuppression was achieved with cyclosporin A
(10 mg $ kg1 $ d1 by mouth), as used in the rabbit model of coronary al-
lograft vasculopathy that was adopted in this study.12 After the experimen-
tal period, rabbits were killed for analysis.
The study protocol was approved by the Animal Ethics Committee of
the University of Sa˜o Paulo.
Heart Graft Surgery
Heterotopic heart graft surgery was performed as described by Alonso
and colleagues.13 Briefly, a right anterior cervicotomy with exposure of
the carotid artery and jugular vein was made in the receptor rabbit. Mean-
while, the donor rabbit was submitted to a median thoracotomy and expo-
sure of the heart; at this point, the animal was heparinized, and explantation
of the heart was made after local hypothermia with 4C Ringer’s lactate.
Transplantation was performed with previous heparinization of the recipi-
ent rabbit through anastomosis of the aorta with the carotid artery and anas-
tomosis of the pulmonary artery with the jugular vein. Graft beating was
monitored by means of daily local palpation.
Plasma Lipids and Blood Cell Counting
Blood samples were taken before the operation and on the day before
death from the marginal ear vein after overnight fasting for determination
of total cholesterol, high-density lipoprotein cholesterol, and triglycerides
with commercial kits (Labtest, Sa˜o Paulo, Brazil) and for blood cell counts.
Preparation of LDE and Association With Paclitaxel
LDE was prepared according to the method described by Maranha˜o and
colleagues.14 LDE was dialyzed against saline solution and passed through
a 0.22-mm filter for the experiments. Paclitaxel oleate synthesis and asso-
ciation to LDE were performed as described previously.9
LDE Tissue Uptake
Four animals of the control group were injected with LDE labeled with
[14C]-cholesteryl oleate ether 24 hours before death. In those animals frag-
ments of the native and heterotopic heart, liver, lungs, spleen, kidney, pan-
creas, and aorta were excised for determination of the LDE radioactivity
uptake by those tissues. This experiment was performed with LDE alone
(ie, without paclitaxel) because previous studies showed that the associa-
tion of paclitaxel to LDE does not change LDE biodistribution.9,11
LDE at a 100-mL volume labeled with [14C]-cholesteryl oleate ether
(PerkinElmer, Boston, Mass) was injected intravenously into the ear veins
of the rabbits. Animals were kept in individual cages for 24 hours, when
they were killed, and plasma samples of 100 mL and tissue samples of
0.25 to 1 g were collected and kept in cold saline solution before lipid
extraction with chloroform/methanol (2:1 vol/vol).15 After extraction, the
solvent was evaporated under N2 flow and resuspended with 500 mL of
chloroform/methanol (2:1 vol/vol), and half the suspension was placed sep-
arately into vials with 5 mL of scintillation solution (Packard BioScience,
Groningen, Netherlands). Radioactivity was measured with a Packard 1600
TR liquid scintillation spectrometer (Palo Alto, Calif).
Analysis of Coronary Artery Elastic Lamina and
Lumen
Animals were killed by means of sodium pentobarbital injection. Both
native and grafted hearts were excised, washed with saline solution, and
fixed on 10% buffered formalin. After fixation, hearts were transversally
cut into 3 portions. The middle portion that contains all 3 main artery types,
(ie, small, middle, and large arteries) was sectioned in 5-mm segments anddiovascular Surgery c Volume 141, Number 6 1523
TABLE 1. Body weight, serum lipid levels, and hematologic profile of heart-grafted control animals and heart-grafted rabbits treated with
LDE–paclitaxel (4 mg/kg body weight per week for 6 weeks)
Control rabbits Rabbits receiving LDE–paclitaxel treatment
Parameters Baseline Sixth week Baseline Sixth week
Body weight (kg) 3.65  0.19 3.43  0.25 3.26  0.13 3.29  0.26
Serum lipids (mg/dL)
Total cholesterol 68  15 563  62* 53  18 579  38*
HDL cholesterol 9  2 17  1* 9  1 14  1
Triglycerides 191  40 210  32 100  24 159  14
Hematologic profile
Red blood cells (109/mL) 5.3  0.2 4.9  0.6 5.2  0.3 4.4  0.3
Leukocytes (106/mL) 6.3  0.6 7.0  0.7 5.4  0.5 7.9  0.9
Lymphocytes (%) 72.1  2.6 73.8  2.1 75.6  4.1 77.4  1.9
Monocytes (%) 9.1  1.2 9.1  1.5 6.7  0.8 8.6  1.1
Neutrophils (%) 18.8  1.8 17.1  1.7 17.7  3.6 14.2  2.0
All animals were treated with cyclosporin A (10 mg $ kg1 $ d1 by mouth). LDE, Cholesterol-rich nanoemulsion; HDL, high-density lipoprotein. *P<.001 versus baseline.
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and with Verhoeff–van Gieson stain. The area of the transverse section
of the coronary arteries was estimated by measuring the internal elastic
lamina and the vessel luminal area. Percentage of stenosis was calculated
from the difference between the luminal area and the internal elastic lamina
area, according to the following formula: Percentage stenosis ¼ Area of
lumenArea of internal elastic lamina/Area of internal elastic lamina.16
Immunohistochemistry of Native and Heterologous
Hearts
Heart sections were labeled with anti–a-actin antibody for vascular
smooth muscle cells (DakoCytomation, Glostrup, Denmark), anti-RAM
11 antibody (DakoCytomation) for macrophages, and CD35 (Abcam,
Cambridge, Mass) for C3b/C4b receptor. All measurements were per-
formed with a Leica QWin Image Analysis Software (Leica Microsystems,
Wetzlar, Germany).
Histologic Evaluation of Myocardium
The inflammatory process of the myocardium of grafted hearts was
graded from 0 to 4 according to the presence of inflammatory cells. Recent
necrosis was graded from 0 to 2. The presence or absence of steatosis, cal-
cification, and hemorrhagewas registered. The analyses were performed by
a pathologist blinded to study group.
Statistical Analysis
Comparison among weight, serum lipids, and hematologic profiles of
the control and LDE–paclitaxel groups at baseline and after the treatment
and between the coronary measurements of hearts of both the control and
LDE–paclitaxel groups were assessed by using 1-way analysis of variance
with Tukey’s post test. Comparison between the uptake of grafted and na-
tive hearts was assessed by using the Student’s t test. Data are expressed as
means  standard errors of the mean.RESULTS
Serum Lipids
Table 1 shows the serum lipids of the rabbits at baseline
and at 6 weeks after transplantation in both the control
group and the rabbits treated with LDE–paclitaxel. There
was a 10-fold increase in serum total cholesterol levels in
both groups (P<.001). The increase in high-density lipo-
protein cholesterol levels was statistically significant only1524 The Journal of Thoracic and Cardiovascular Surin control rabbits. Triglyceride values were unchanged
either in rabbits receiving LDE–paclitaxel treatment or in
control animals.
Body Weight and Hematologic Profile
In respect to the parameters related to the toxicity of
LDE–paclitaxel treatment, there was no change in body
weight from baseline to 6 weeks after transplantation in
the group treated with LDE–paclitaxel (Table 1). There
was also no change in the control group. The measured he-
matologic parameters, such as red blood cell and leukocyte
counts and differential leukocyte counts, did not change at
6 weeks after transplantation in any group.
Tissue Uptake of LDE
The uptake of LDE by the native and grafted heart tissues
is shown in Figure 1. After injection, the LDE label was
concentrated in the grafted hearts almost 4-fold compared
with that seen in native hearts (21.3%  5.2% and
6.0%  2.1%, P ¼ .0313). Regarding the other analyzed
tissues, the liver was the main uptake site of LDE
(27.0%  3.3%), followed by the lungs (16.0% 
3.0%), aorta (10.7%  5.9%), spleen (10.3%  1.9%),
kidney (4.1%  0.3%), pancreas (3.6%  1.0%), and
muscle (0.9%  0.2%). There was no difference in LDE
tissue uptake between the grafted heart and the liver.
Coronary Stenosis and Inflammatory Rejection
Process
As shown in Table 2, treatment with LDE–paclitaxel re-
duced the degree of stenosis in the coronary arteries of the
grafted hearts by roughly 50% (P<.001). The luminal area
in the group receiving LDE–paclitaxel treatment was 3-fold
larger than that seen in the control group (P<.05). In both
groups the coronary arteries of native hearts showed no
stenosis. Table 2 also shows the percentage of area with
macrophage staining in animals receiving LDE–paclitaxelgery c June 2011
FIGURE 1. Uptake by different tissues of cholesterol-rich nanoemulsions labeled with [14C]-cholesteryl oleate ether 24 hours after intravenous injection
into rabbits. *P ¼ 313 versus native heart. Data are expressed as percentage uptake and normalized by gram as means  standard errors of the mean.
Lourenc¸o-Filho et al Evolving Technology/Basic Sciencetreatment and in control animals. LDE–paclitaxel treatment
resulted in a 7-fold order reduction in the macrophage infil-
trate. CD35 staining was not affected by treatment with
LDE–paclitaxel.
Figure 2 shows the coronary arteries of native and grafted
hearts of animals receiving LDE–paclitaxel treatment and
control animals. In the grafted hearts it is seen that the treat-
ment with LDE–paclitaxel reduced the width of the intima
and inhibited the destruction of the medial layer in compar-
ison with control hearts. In respect to the macrophage-
staining images, LDE–paclitaxel drastically reduced the
presence of those cells in myocardial tissue sections. The
presence of CD35 in the treated and control groups is also
shown in the micrographs.
Histologic Evaluation of Myocardium
Regarding the histologic evaluation of the grafted hearts,
the intensity of inflammation in the myocardium was lower
in the rabbits receiving LDE–paclitaxel treatment than in
control rabbits. On the other hand, necrosis was less intense
in the treated animals than in the control animals: necrosis
was grade 0 in 4 treated animals and in only 1 of the control
rabbits, whereas grade 1 was found in 5 treated and 6 con-TABLE 2. Coronary arterymeasurements and percentages of macrophage
microscopy morphometry and immunohistochemistry in heart-grafted con
(4 mg/kg body weigh per week for 6 weeks)
Control rabbits
Native heart Heart gra
Morphometry
Elastic lamina area (mm2) 16.31  1.79 137.43  45
Arterial luminal area (mm2) 16.31  1.79 10.79  4.0
Stenosis (%) 0 83.74  8.0
Immunohistochemistry
Macrophages (%) 0.26  0.14 14.96  6.7
CD35 (%) 0.61  0.47 3.09  1.2
All animals were treated with cyclosporin A (10 mg $ kg1 $ d1 by mouth). LDE, Cholest
control hearts. zP<.05 versus heart-grafted control animals. xP<.05 versus heart-grafted
The Journal of Thoracic and Cartrol rabbits, and grade 2 was found in 2 treated and 3 control
rabbits. Steatosis was found in the grafts of 5 treated and 7
control rabbits. Calcification was found in 4 treated and 6
control rabbits, but hemorrhage was present in 6 rabbits
receiving LDE–paclitaxel treatment and only in 2 control
rabbits. Thus the microscopic observations favored the
assumption that LDE–paclitaxel treatment improved the
overall histologic status of the grafts.
DISCUSSION
In this study LDE showed the ability to concentrate in the
grafted heart. The increase in uptake of LDE by the graft,
which was almost 4-fold that of the native heart, was prob-
ably due to overexpression of LDL and other lipoprotein re-
ceptors. Initially described by Ho and coworkers17 in
neoplastic cells, it was subsequently shown that receptor
overexpression also occurs in nonneoplastic proliferative
processes, such as in hyperplastic intimal cells of athero-
sclerotic lesions.18 We described an increase in LDE clear-
ance, suggesting receptor overexpression in patients with
thalassemia minor19; in such patients excessive red blood
cell destruction leads to increased turnover of bone marrow
cell precursors. LDL receptor overexpression is thus relatedinvasion and of the rejectionmarker (CD35) obtained bymeans of light
trol animals and in heart-grafted rabbits treated with LDE–paclitaxel
Rabbits receiving LDE–paclitaxel treatment
ft Native heart Heart graft
.25y 31.03  5.13z 66.27  13.27
6 31.03  5.13 33.08  8.35x
6 0 38.04  8.09k
5* 0.10  0.03z 2.36  1.41
0 1.97  0.99 4.00  1.38
erol-rich nanoemulsion. *P<.05 versus native control hearts. yP<.01 versus native
control animals. kP<.001 versus heart-grafted control animals.
diovascular Surgery c Volume 141, Number 6 1525
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FIGURE 2. Immunohistochemistry of myocardial and arterial tissues from native and grafted hearts. Photomicrographs of 3,30-Diaminobenzidine chro-
mogen immunostaining for macrophages (A; RAM-11), (B) CD35, (C) a-actin, and (D) elastic lamina stained with Verhoeff–van Gieson stain. (Original
magnifications: 1003 [A, C, and D] and 2003 [B].)
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mitosis rates in the building of new cell membranes. More
recently, we showed that LDE also concentrates in lesional
aortas of atherosclerotic rabbits.6 Conceivably, overexpres-
sion of LDL receptors in the inflammatory and proliferating
cells is the factor that leads to the increased LDE uptake by
the graft.
LDE is made without protein, but when it is injected into
the bloodstream, it acquires apolipoprotein E from the na-
tive lipoproteins or free unassociated apolipoprotein E.
Apolipoprotein E is recognized by LDL receptors and
thus can bridge the internalization of the lipoprotein by
means of receptor-mediated endocytosis.5,20 In this setting
it offers a powerful mechanism to target drugs to the
graft, aiming to control the inflammatory–proliferative
process associated with organ transplantation by using
LDE as a carrier. Pharmacokinetic studies in animals9 and
patients with cancer10,11 have shown that paclitaxel does
not dissociate from LDE in the circulation until
internalization, together with the carrier, through the LDL1526 The Journal of Thoracic and Cardiovascular Surreceptor’s endocytic pathway. Therefore the remarkable
uptake of LDE in the grafted heart, which was roughly
4-fold that of the native heart, implies that paclitaxel
associated with LDE was concentrated in the graft 4-fold
more than in the native heart.
The toxicity of antiproliferative agents currently used in
cancer treatment prevents their systemic use in patients with
cardiovascular diseases. Association with LDE, however,
has pronouncedly reduced the side effects, as shown in
experimental studies with LDE–paclitaxel in animals
and in patients with advanced cancer, in whom no toxicities
were reported.9,10 The tolerability of other antiproliferative
drugs that, similarly to paclitaxel, convey severe toxicity,
such as carmustine and etoposide, was dramatically
improved by association with LDE, as shown at the
clinical trial level.21,22 This virtual lack of toxicity was
also shown in rabbits in the current study and can be
ascribed to the new biodistribution created by the LDE
system, as well as to the slowing down of the removal of
the drug from the circulation. On association with LDE,gery c June 2011
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tested to date (ie, etoposide, carmustine, and paclitaxel),
slower than those of the drug alone or with currently used
commercial vehicles. Another possibility stems from the
fact that sequestration of the drug into the nanoparticle
structure avoids direct contact of the drug with the
circulating media. Although in this study lack of toxicity
was documented only by body weighing and blood cell
counting, a more complete documentation was made in
patients with cancer.21
The uptake of LDE by the grafted heart was roughly as
great as LDE liver uptake. The liver is the main uptake or-
gan for both native LDL and LDE because it concentrates
the bulk of LDL receptors in the body. Nonetheless, in
our previous studies it has been shown that LDE–paclitaxel
did not elicit hepatotoxicity, such that in future clinical trials
this might not be a major concern.
Coronary allograft vasculopathy has an important athero-
sclerotic component that involves features of risk factors for
ischemic heart disease, such as dyslipidemia, which in this
study was elicited by feeding the animals with cholesterol.
The immunologic challenge, infection by different agents
and other postgraft factors, diabetes, and arterial hyperten-
sion have also been postulated in the pathogenesis. Worsen-
ing of graft vascularization is the hallmark of coronary
allograft vasculopathy, regardless of whether rejection or
the atherosclerotic component of the disease is predomi-
nant. In this study treatment with LDE–paclitaxel resulted
in a clear-cut improvement in the vascularization of the
graft compared with that seen in control animals. This ef-
fect, reflected in a 3-fold increase in vessel luminal area
and reduction of 50% in stenosis, has the ability to dramat-
ically improve myocardial perfusion. This would strongly
contribute to improving the graft dysfunction that leads to
cardiac failure and compromises the success of a substantial
number of grafting procedures. Paclitaxel’s potent antipro-
liferative action was conceivably responsible for this effect,
but actions of the drug on the immunologic response23,24
could also have played a role in this outcome. A
remarkable reduction in macrophage infiltration achieved
by LDE–paclitaxel treatment is shown in the images of
immunohistochemical staining shown in Figure 2. The im-
munoregulatory action of the treatment is clearly demon-
strated in this key arterial inflammatory–proliferative
process. Immunostaining with a-actin unraveled the protec-
tive effect of the treatment against medial layer destruction
induced by transplantation.
The anatomopathological study of the grafted hearts
showed that LDE–paclitaxel treatment led to an apparent
general improvement in several pathologic changes result-
ing from heterologous grafting. In respect to necrosis, the
most important histologic alteration consequent to grafting,
there was a clearly observable protective effect offered by
LDE–paclitaxel. The presence of hemorrhagic sites was,The Journal of Thoracic and Carhowever, greater in the rabbits receiving LDE–paclitaxel
treatment. A possible interpretation of this finding lies in
the fact that vessel occlusion leads initially to hemorrhage
and only subsequently to necrosis. As in the treated animals,
arterial obstruction is delayed. Hemorrhage is also delayed
and appears more intensively by the time the animals are
killed, whereas in the control animals the hemorrhage pro-
cess was already resolved, and the presence of necrosis was
already predominant. Regarding the beneficial effects of
LDE–paclitaxel on grafted heart steatosis we described
here, those effects might be ascribed to the observed reduc-
tion of the inflammatory process. This leads to restoration of
the negative feedback of LDL receptors that is disrupted by
inflammation.25 Consequently, less fat is stored in the
grafted heart, resulting in less steatosis.
In conclusion, this study shows that the introduction of
a powerful antiproliferative drug carried in a vehicle that
has targeting properties improves the posttransplantation
injury to the grafted heart. This novel therapeutic approach
should be tested in a future clinical pilot trial aiming to en-
sure nontoxicity and potential benefits for patients undergo-
ing heart transplantation.
We thank Dr Paulo Saldiva for the histopathological analysis.References
1. Eisen HJ. Immunossupression on the horizon. Heart Failure Clin. 2007;3:43-9.
2. Chan M, Pearson GJ. New advances in antirejection therapy. Curr Opin Cardiol.
2007;22:117-22.
3. Khan UA, Williams SG, Fildes JE, Shaw SM. The pathophysiology of chronic
graft failure in the cardiac transplant patient. Am J Transplant. 2009;9:2211-6.
4. Suzuki J, Isobe M, Morishita R, Nagai R. Characteristics of chronic rejection in
heart transplantation: important elements of pathogenesis and future treatments.
Circ J. 2010;74:233-9.
5. Maranha˜o RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM,
Coelho IJ, et al. Plasma kinetics and biodistribution of a lipid emulsion resem-
bling low-density lipoprotein in patients with acute leukemia. Cancer Res.
1994;54:4660-6.
6. Maranha˜o RC, Tavares ER, Padoveze AF, Valduga CJ, Rodrigues DG,
Pereira MD. Paclitaxel associated with cholesterol-rich nanoemulsions promotes
atherosclerosis regression in the rabbit. Atherosclerosis. 2008;197:959-66.
7. Rowinsky EK, Cazenave LA, Doneiiower RC. Taxol—a novel investigational
antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247-59.
8. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS,
Grochow LB, et al. Phase I and pharmacologic study of paclitaxel and cisplatin
with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-lim-
iting. J Clin Oncol. 1993;11:2010-20.
9. Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibanez OC,
et al. Improvement of paclitaxel therapeutic index by derivatization and associ-
ation to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer
Chemother Pharmacol. 2005;55:565-76.
10. Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranha˜o RC. Use
of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to
paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and
a pilot clinical study. Cancer Chemother Pharmacol. 2009;63:281-7.
11. Dias MLN, Carvalho JP, Rodrigues DG, Graziani SR, Maranha˜o RC. Pharmaco-
kinetics and tumor uptake of a derivatized form of paclitaxel associated to a cho-
lesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer
Chemother Pharmacol. 2007;59:105-11.
12. Andersen HO, Madsen G, Nordestgaard BG, Hansen BF, Kjeldsen K, Stender S.
Cyclosporin suppresses transplant arteriosclerosis in the aorta-allografted, cho-
lesterol-clamped rabbit. Suppression preceded by decrease in arterial lipoprotein
permeability. Arterioscler Thromb. 1994;14:944-50.diovascular Surgery c Volume 141, Number 6 1527
Evolving Technology/Basic Science Lourenc¸o-Filho et al
E
T
/B
S13. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarter-
iosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection
and hypercholesterolemia. Am J Pathol. 1977;87:415-42.
14. Maranha˜o RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Met-
abolic behavior in rats of a non-protein microemulsion resembling low density
lipoprotein. Lipids. 1993;28:691-6.
15. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and pu-
rification of total lipids from animal tissues. J Biol Chem. 1957;206:2443-50.
16. Foegh ML, Khirabadi BS, Chambers E, Amamoo S, Ramwell PW. Inhibition of
coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octa-
peptide. Atherosclerosis. 1989;78:229-36.
17. HoYK,SmithRG,BrownMS,Goldstein JL.Low-density lipoprotein (LDL) recep-
tor activity in human acutemyelogenous leukemia cells.Blood. 1978;52:1099-114.
18. Bujo H, Saito Y. Modulation of smooth muscle cell migration by members of the
low-density lipoprotein receptor family. Arterioscler Thromb Vasc Biol. 2006;26:
1246-52.
19. Naoum FA, Gualandro SF, Latrilha MC, Maranha˜o RC. Plasma kinetics of a cho-
lesterol-rich microemulsion in subjects with heterozygous beta-thalassemia.
Am J Hematol. 2004;77:340-5.1528 The Journal of Thoracic and Cardiovascular Sur20. Maranha˜o RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH.
Metabolic behavior in rats of a non-protein microemulsion resembling low
density lipoprotein. Lipids. 1993;28:691-6.
21. Maranha˜o RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC,
Rodrigues DG, et al. Association of carmustine with a lipid emulsion: in vitro,
in vivo and preliminary studies in cancer patients. Cancer Chemother Pharma-
col. 2002;49:487-98.
22. Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CH, Rodrigues DG,
Maranha˜o RC. Use of a cholesterol-rich microemulsion that binds to low-
density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol.
2003;55:1615-22.
23. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol
Immunother. 2000;49:181-5.
24. Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is
not always better. Int J Oncol. 2001;18:417-24.
25. Chen Y, Ruan XZ, Li Q, Huang A, Moorhead JF, Powis SH, Varghese Z. Inflam-
matory cytokines disrupt LDL-receptor feedback regulation and cause statin
resistance: a comparative study in human hepatic cells and mesangial cells.
Am J Physiol Renal Physiol. 2007;293:680-7.gery c June 2011
